New antibiotic compound enters phase 1 clinical trial
8 November 2011 Novacta Biosystemmber 2011s has commenced dosing of the first healthy volunteers in…
read moreNovacta is a drug discovery and development company using pathway engineering and chemistry to optimise the activity of natural products for the treatment of infectious diseases. The company combines proprietary technologies from the world-renowned Actinomycete group of the John Innes Centre, Norwich with the know-how of a highly experienced team drawn from major pharmaceutical companies and the biotechnology industry.
Status current
Associated Fund UK Innovation & Science Seed Fund
Sector Medical / Biotechnology
Website www.novactabio.com/
8 November 2011 Novacta Biosystemmber 2011s has commenced dosing of the first healthy volunteers in…
read moreUpdate your browser to view this website correctly.Update my browser now